

Empower Clinics Wholly Owned Subsidiary MediSure Receives Approval of Health Canada Medical Device Establishment Licence (MDEL)

MediSure Canada has obtained a Health Canada Medical Device Establishment License (MDEL # 17716), to Source Class II through Class IV Diagnostic and Therapeutic Medical Devices

VANCOUVER BC: August 17, 2021 – EMPOWER CLINICS INC. (CBDT:CSE) (SEC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company”) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce that Medi+Sure Canada Inc. (“**MediSure**”) a wholly owned subsidiary, has obtained Health Canada Medical Device Establishment License (MDEL # 17716), to source class II (two) to class IV (four) diagnostic and therapeutic medical devices from MDALL licensed manufacturers located across the world, and distribute these medical devices in Canada under the MediSure brand.

“The achievement of MediSure receiving the new MDEL licence from Health Canada is a major accomplishment, as it complements our existing Health Canada MDALL manufacturing license, and immediately opens the door for MediSure to launch new, innovative medical device solutions into the Canadian healthcare market.” said Mario Cortis, MediSure, President.

EMPOWER ACCELERATES ABILITY TO DISTRIBUTE AND SELL MEDICAL DEVICE PRODUCTS IN CANADA WITH THE MEDISURE BRAND

“One in four Canadian’s, and one in four American’s are afflicted with various forms of diabetes, and as such, we must use our resources to advance care and treatment options for patients.” said Steven McAuley, Chairman & CEO, Empower Clinics Inc. “We also must expand our reach into new technologies, new devices, new ways to deliver care. We must use The Medi-Collective. We are going to pilot new technology. MediSure as a division, as a company, has already made an impact, and I am certain much more impact will come from the MediSure brand in North American markets now that the MDEL licence is officially granted.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management <https://agoracom.com/ir/EmpowerClinics>

ABOUT MEDISURE:

MediSure Canada is a Canadian medical device company dedicated to bringing value to the high cost of diabetes, both to patients and insurers. MediSure’s products are designed and manufactured with safety and durability in mind, meeting all ISO standards with world-class quality controls. Equipped with features that lead the industry in technology, MediSure’s products are designed to offer a user-friendly experience and an overall improved approach to diabetes management.

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
CEO
s.mcauley@empowerclinics.com
604-789-2146

Investors: Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health tele dermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion in 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will

occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether because of new information, future events or otherwise, except as expressly required by applicable laws.